Thor in contract for two Riverside Drive apartment buildings

TRD New York /
Dec.December 18, 2013 03:05 PM

Thor Equities’ residential division is in contract to purchase two Upper West Side apartment buildings for more than $80 million.

The two properties, located at 120 and 125 Riverside Drive at West 84th Street, have a total of 93 units between them, the New York Post reported. No. 120 was constructed in 1907 and stretches nine stories tall, while 125 Riverside, built the same year, is 12 stories. Together, the two buildings span more than 135,000 square feet, according to PropertyShark data.

Thor’s Joseph Sitt partnered with Alan Klein and Jonathan Fishman, both formerly of Stonehenge Partners, to launch Thor Equities’ new residential division in October. Though the firm currently owns a stake in brokerage TOWN Residential, the move was otherwise a first for the company, which has over 15 million square feet of space in cities around the world.

The Steven Vegh of Westwood Realty Associates represented both sides in the deal, a source told The Real Deal.

Thor did not return the Post’s request for comment. [NYP, 4th item] Julie Strickland

Related Articles

Thor Equities' Joe Sitt and a closeup of 545 Madison Avenue (Credit: Google Maps)

Thor Equities loses 545 Madison Avenue

The Chicago condo deconversion craze is dying

Clockwise from left: 270 Richards Street in Brooklyn, 72-01 Queens Boulevard in Queens, and 2069 Bruckner Boulevard in the Bronx (Credit: Thor Equities, EDI International, and Azimuth)

The top 10 biggest real estate projects coming to NYC

Joe Sitt and 1725 Shore Parkway in Bensonhurst (Credit: Google Maps)

Thor sells Bensonhurst big-box store for $75M

545 Madison Avenue and Thor Equities CEO Joe Sitt (Credit: Google Maps)

Thor Equities on the verge of losing another building in Manhattan

AOC unveils rent regulation plan, Hong Kong real estate stocks are sinking: Daily digest

Introducing ThorLogis, Thor Equities’ ambitious plan to break into logistics and e-commerce

Thor is breaking into the life sciences industry